Drug intelligence / Profile preview

TRS-023

Development stage: Preclinical
Lead developer: Zhejiang Teruisi Pharmaceutical

Overview

TRS-023 is a drug candidate currently in preclinical development by Zhejiang Teruisi Pharmaceutical Co., Ltd. It is being investigated for its potential therapeutic use in neoplasms. Further details regarding its specific mechanism of action, targets, and modalities are not publicly available at this stage of development.

Beyond the preview

Go deeper on TRS-023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRS-023.

Explore the full profile